The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
The impact of liraglutide on renal fibrosis in rats with diabetes type 2
Author(s): 
Pages: 6-8
Year: Issue:  1
Journal: Qilu Pharmaceutical Affairs

Keyword:  利拉鲁肽Toll样受体4转化生长因子-β1结缔组织生长因子;
Abstract: 目的 探究利拉鲁肽在糖尿病致肾脏纤维化过程中的影响及作用机制.方法 随机选取大鼠20只,为正常组(NC组);40只经高脂高糖结合链脲佐菌素注射复制糖尿病大鼠模型,再随机分为糖尿病组(DM组)、利拉鲁肽组(LR组);利拉鲁肽皮下注射,0.15 mg·(kg·d)-1,正常组、糖尿病组给予等体积的溶媒.给药8周后检测24 h尿蛋白排泄(24 hUP)、尿素氮(BUN)、血清肌酐(SCr)水平.光镜下观察大鼠肾脏病理.Toll样受体4由免疫组化法检测.酶联免疫吸附测定(ELISA)检测转化生长因子-β1、结缔组织生长因子含量.结果 与正常组比较,利拉鲁肽组24 h尿蛋白排泄、尿素氮、血清肌酐水平升高(P<0.05),Toll样受体4表达增加(P<0.05),肾脏纤维化程度加深;与糖尿病组比较,利拉鲁肽组24 h尿蛋白排泄、尿素氮、血清肌酐水平下降(P<0.05),Toll样受体4表达减少(P<0.05),纤维化程度好转.结论 利拉鲁肽能够改善肾脏纤维化,其机制可能与抑制Toll样受体4通路有关.
Related Articles
No related articles found